Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented chronic (at least 6 months) HCV GT 1 infection (with no evidence of mixed genotypes or genotype that cannot be assigned a type)~* Evidence or no evidence of liver cirrhosis based on one of the following:~* Liver biopsy performed within 24 months of Day 1 (if participant is cirrhotic then there is no time restriction on biopsy)~* Fibroscan performed within 12 months of Day 1 of this study~* Fibrosure™ (Fibrotest™) plus aspartate aminotransferase to platelet Ratio Index \[APRI\] obtained during the screening period)~* Has HCV status that is one of the following:~* Treatment naïve~* Prior interferon or pegylated interferon with or without ribavarin failures (null responder, partial responder, or relapser)~* Intolerant to prior interferon or pegylated intereferon with or without ribavarin regimen~* Chronic kidney disease (defined as glomerular filtration rate \[eGFR\] \<=29) non-dialysis dependent or on hemodialysis for at least 3 months, including individuals awaiting kidney transplant and those with failed kidney transplants but no longer on immunosuppressant therapy)~* Female participant of reproductive potential must agree to remain abstinent or use (or have their partner use) 2 acceptable methods of contraception from at least 2 weeks prior to Day 1 through 14 days after the last dose of study drugs, or longer if dictated by local regulations~Exclusion Criteria:~* Evidence of decompensated liver disease~* On peritoneal dialysis for management of kidney disease~* Co-infection with hepatitis B virus or human immunodeficiency virus (HIV)~* History of malignancy \<=5 years prior to signing informed consent~* Clinical diagnosis of substance abuse~* Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from Day 1 through 14 days after the last study dose, or longer if dictated by local regulations~* Organ transplant (including hematopoietic stem cell transplant) other than kidney, cornea, and hair~* Conditions requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* Uncontrolled or poorly controlled hypertension~* Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina) or cardiovascular procedure within 3 months prior to signing informed consent~* New or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent~* Severe active peripheral vascular disease~* Recent (within 3 months prior to signing informed consent) episode or recurrence of stroke, transient ischemic attack (TIA) or neurological disorder, including but not limited to seizures~* Evidence or history of chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Treatment (Type: EXPERIMENTAL): Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
- Deferred Treatment (Type: EXPERIMENTAL): Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
- Intensive PK (Type: EXPERIMENTAL): Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).